MARC Record from Library of Congress

LEADER: 02148cam a22004697a 4500
001 2009933609
003 DLC
005 20101231083117.0
008 090728s2010 gw a b 000 0 eng
010 $a 2009933609
015 $aGBA982612$2bnb
016 7 $a101524883$2DNLM
016 7 $a015352822$2Uk
020 $a9783642012211 (hbk. : alk. paper)
020 $a3642012213 (hbk. : alk. paper)
020 $a3642012221 (ebk.)
020 $a9783642012228 (ebk.)
035 $a(OCoLC)ocn495596327
040 $aNLM$cNLM$dUKM$dYDXCP$dVRC$dPAU$dGEBAY$dY9D$dDLC
042 $aukblcatcopy$anlmcopyc$alccopycat
050 00 $aRC268.4$b.S62 2010
050 14 $aRC261$b.R35 v.184 2010
060 00 $aW1$bRE106P v.184 2010
060 10 $aQZ 267$bS635 2010
082 04 $a616.994061$222
245 00 $aSmall molecules in oncology /$cUwe M. Martens (ed.).
260 $aHeidelberg ;$aLondon :$bSpringer,$cc2010.
300 $axvi, 238 p. :$bill. ;$c25 cm.
490 0 $aRecent results in cancer research ;$v184
504 $aIncludes bibliographical references.
505 0 $aProtein kinase inhibitors -- Imatinib mesylate -- Erlotinib -- Axitinib -- Lapatinib -- Sorafenib -- Sunitinib -- Dasatinib -- Nilotinib -- Bosutinib -- Epigenetic modifiers -- Decitabine -- 5-Azacytidine/Azacitidine -- Cell cycle inhibitors -- Bortezomib -- Temsirolimus -- Danusertib (formerly PHA-739358): a novel combined pan-aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor -- BI 2536: targeting the mitotic kinase polo-like kinase 1 (Plk1) -- Other novel agents -- Imetelstat (GRN163L): Telomerase-based cancer therapy -- GDC-0449: targeting the hedgehog signaling pathway.
650 0 $aCancer$xMolecular aspects.
650 0 $aAntineoplastic agents.
650 0 $aCancer$xTreatment.
650 12 $aNeoplasms$xdrug therapy.
650 22 $aAntineoplastic Agents$xtherapeutic use.
650 22 $aAzacitidine$xtherapeutic use.
650 22 $aProtein Kinase Inhibitors$xtherapeutic use.
650 07 $aCytostatikum$2swd
650 07 $aKleines Molekül$2swd
700 1 $aMartens, Uwe M.
830 0 $aRecent results in cancer research ;$v184.